|
The Last Time This CEO Took Over A Biotech Company- They Catapulted From $3M To $350M Now, he might be creating this 116.6X return again, maybe even bigger. This little-known Biotech outfit has a patent-pending with the FDA for a game changing medical invention. One that has the potential to make this biotech stock worth knowing about. If history repeats itself, could the CEO lead another Biotech stock to 116.67X gains? Some top investors say yes: 116.67X Growth? This Could Be 2024's Top Biotech Pick THIS IS A PAID ADVERTISEMENT
|
If you no longer wish to receive our emails, click the link below:
Unsubscribe
DailyMarketAlerts c/o CLM Media LLC 315 Ridgedale Avenue #556 East Hanover, New Jersey 07936 United States
No comments:
Post a Comment